Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes

Table 1

The capability of antibodies against CD14 affects the LPS-induced effects (the references are indicated inside the square brackets).

Clone (isotype)	Epitope	Influence on LPS-induced effects		References
		Does	Does not
3C10 (mIgG2b); Effectiveness decreases when LPS concentration increases	E7–R14	(1) Suppress CD14 binding to LBP·Re-LPS Salmonella minnesota (1 ng/ml) as well as PMN priming for fMLP-triggered О2^⋅−/ROS; (2) Whole or F(ab)2 suppress О2^⋅−/ROS production in monocytes challenged by Re-LPS Escherichia coli (1 ng/ml, 5% blood serum); (3) Prevent CD11b/CD18 mobilization to the cell surface in PMNs stimulated by Ra/Rb-LPS E. coli K12 (30 ng/ml, without serum)		[90–96]
biG10 (mIgG1)	D9–F13	(1) Suppress TNF-α production in whole human blood exposed to LPS Salmonella abortus-equi (10 ng/ml)		[97, 98]
MY4 (mIgG2b)	S34–G44	(1) Suppress CD14 binding to LBP·Re-LPS; (2) Decrease PMN priming by LPS from E. coli O55:B5 (10 ng/ml, 1% serum) or E. coli O111:B4 (10 ng/ml, 10% serum); (3) Inhibit phosphatidic acid generation in LPS-primed and fMLP-stimulated PMNs; (4) Suppress LPS-dependent activation of p38 MAPK in human PMNs; (5) Whole or Fab suppress LPS uptake by human monocytes	(1) Affect fMLP-triggered О2^⋅−/ROS production from unprimed PMNs	[77, 94, 99–104]
60bca (mIgG1)	S34–V38	(1) Prevent LBP·Re-LPS S. minnesota binding to CD14; (2) Abolish almost completely PMN priming by LBP·Re-LPS S. minnesota (1 ng/ml) for fMLP-triggered О2^⋅−/ROS		[90, 105]
63D3 (mIgG1)		(1) Whole or F(ab)2 suppress weakly LPS-induced ROS production in human monocytes	(1) Prevent LBP-dependent delivery of Re-LPS S. minnesota to CD14; (2) Suppress LPS-induced TNF-α and IL-8 production	[91, 94, 95, 106–108]
28C5 (mIgG1)		(1) Suppress LBP-dependent delivery of Re-LPS S. minnesota to CD14; (2) Suppress LPS-dependent activation of p38 MAPK		[94, 109]
biG14 (mIgG2a)	E39–G44	(1) Decrease binding of Ra-LPS E. coli to CD14		[97]
UCHM-1 (mIgG2a)		(1) Suppress LPS-induced IL-8 production by human retinal pigment epithelial cells; (2) Decrease PMN priming by S- or Re-LPS E. coli (100 ng/ml, 2% serum) for fMLP-triggered О2^⋅−/ROS production		[14, 110]